BI-1607 clinical trials

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

This study is testing a new drug, BI-1607, combined with two existing cancer drugs, pembrolizumab and ipilimumab, for advanced melanoma. Researchers want to see if this new combination is safe, effective, and helps patients whose cancer hasn't responded to other treatments.